IMS Highlights for Triple Class Refractory Myeloma | Sagar Lonial, MD, FACP | IMS 2023

Triple class refractory multiple myelomaПодробнее

OS with Cilta-cel vs SOC in Lenalidomide Refractory MM | María-Victoria Mateos, MD, PhD | IMS 2024Подробнее

Carfilzomib and panobinostat for R/R multiple myeloma: Phase I resultsПодробнее

Does Dexamethasone Cause Cataracts? | Rahul Banerjee, MD, FACP | IMS 2023Подробнее

Sagar Lonial, MD, FACP, Talks Multiple Myeloma Highlights from the Summer ConferencesПодробнее

Sagar Lonial, MD, FACP, on Multiple Myeloma Awareness MonthПодробнее

Dr. Lonial Discusses Novel Agents in Multiple MyelomaПодробнее

The HemOnc Pulse Live at ASH: Sagar Lonial, MD, FACP, on Role of Transplant, MRD in MyelomaПодробнее

Dr. Lonial on Novel Mechanisms in Multiple MyelomaПодробнее

Dr. Lonial on the Results of the DREAMM-2 Trial in Multiple MyelomaПодробнее

Myeloma Treatment Selection: CAR-T Versus Bispecific T-Cell Engagers, Bridging Therapy OptionsПодробнее

Treatment challenges in the age of immunotherapyПодробнее

SOHO Saudi Arabia (DAY 5) - Dr Sagar LonialПодробнее

Final Analysis of the Phase 3 TOURMALINE-MM1: Ixazomib + Lenalidomide-Dex Vs Placebo-Rd in RRMMПодробнее

Sagar Lonial, MD on elotuzumab for mutliple myeloma patientsПодробнее

Dr. Sagar Lonial on Understanding Multiple MyelomaПодробнее

Highlights from IMS 2024: key clinical trials presentedПодробнее